162 studies on Thymosin class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This trial holds significant promise as it investigates a novel approach to potentiate the effectiveness of neoadjuvant therapy for resectable NSCLC, a patient population with high unmet medical needs. If the addition…
If the anticipated safety and efficacy signals are observed, this study could pave the way for a new, targeted treatment approach for gynecologic cancers. Oncolytic viruses like KD01 offer a dual mechanism of action: …
If successful, this trial could demonstrate that recombinant human interferon alpha-1b nasal drops, potentially combined with thymosin alpha 1, offer a safe and effective strategy for preventing 2019-nCOV infection. T…
This study is significant because it explores a novel strategy to enhance anti-tumor immunity in a challenging patient population: metastatic NSCLC patients with stable disease after initial TKI therapy. The bold comb…
Preventing infections is paramount for improving survival and quality of life in patients undergoing allogeneic hematopoietic transplantation. If Thymosin Alfa 1 demonstrates a favorable safety profile and preliminary…
If successful, this study could establish Thymosin Alpha1 as a novel therapeutic option for a challenging condition with limited current treatments. Given the widespread prevalence of osteoporotic pain in the elderly,…
This study represents a crucial step towards revolutionizing the management of acute aortic dissection by introducing AI-driven precision medicine. If successful, it could establish a robust "subtyping-target-treatmen…
This review highlights the critical role of pineal gland peptides in potentially combating age-related immune decline by preserving thymus function. The finding that epithalamin and epitalon are particularly effective…
This review significantly advances our understanding of the neuroimmunomodulatory axis and its role in aging, particularly highlighting the potent geroprotective potential of pineal peptides. The finding that pineal p…
These findings suggest that Thymosin alpha-1 represents a promising therapeutic agent for NSCLC, particularly by targeting the immunosuppressive tumor microenvironment. Its ability to block MDSC accumulation through V…
If the TRACE trial demonstrates that Thymosin alpha 1 is effective in preventing IPN, it would represent a significant breakthrough in the management of severe pancreatitis. Currently, there are no specific pharmacolo…
This groundbreaking research powerfully highlights the potential of Thymosin alpha 1 as a novel and effective therapeutic agent for addressing the complex systemic complications of cystic fibrosis, offering a much-nee…
This meta-analysis provides compelling evidence that Thymosin alpha-1 can significantly augment the antiviral effects of Entecavir in patients with HBV-related cirrhosis, leading to better viral control and improved l…
This study provides crucial insights into the gender-specific immune dysregulation observed in COVID-19, highlighting lower T-cell counts and higher inflammation in males. The finding that males with severe disease al…
This study provides compelling evidence that thymosin α1 can significantly improve survival rates in critically ill COVID-19 patients, highlighting its potential as a crucial adjunctive therapy. The observed reduction…
This comprehensive review underscores the significant, yet often underappreciated, therapeutic potential of Thymosin alpha 1 as a broad-spectrum immune modulator with direct antiviral capabilities. The findings strong…
This research highlights the profound potential of PASylation to significantly improve the therapeutic profile of immunomodulatory peptides like Thymosin α1, offering a long-acting formulation that could drastically r…
This study provides compelling in vitro evidence that Thymosin Alpha 1 can effectively mitigate the cytokine storm observed in COVID-19 patients at a cellular level. The ability to dampen excessive inflammation withou…
These findings suggest that Thymosin Alpha 1 could serve as an effective early intervention for non-severe COVID-19, potentially preventing disease worsening and accelerating recovery. The significant reduction in pro…
This study provides compelling evidence that Thymosin alpha-1 can significantly improve both overall and recurrence-free survival in patients with HBV-related HCC after curative surgery. The observed 40% reduction in …
This research provides compelling evidence for a novel and highly effective combination therapy for Nasal NK/T-cell Lymphoma, a particularly aggressive and hard-to-treat cancer. The synergistic action of Gemcitabine a…
This case report underscores the vital role of ECMO as a life-saving intervention for postpartum women experiencing severe COVID-19-related ARDS refractory to conventional treatments. It provides valuable insights int…
This study provides compelling real-world evidence supporting the immunomodulatory benefits of Thymosin Alpha 1 in managing COVID-19, particularly in reducing mortality and disease severity. The observed improvements …
This research highlights the significant potential of thymosin α1, an immunomodulatory peptide, to improve long-term survival and reduce recurrence in non-small cell lung cancer patients following curative surgery. Th…
This preliminary safety assessment provides critical foundational data, validating the non-toxic nature of Prothymosin α and ProTα(100-109) at high acute doses. The absence of adverse effects significantly de-risks th…
This study provides compelling evidence that thymosin alpha 1 can serve as a valuable adjunctive therapy for pulmonary tuberculosis patients also suffering from diabetes, significantly enhancing both clinical efficacy…
This research highlights a novel mechanism by which Thymosin-α1 can influence respiratory epithelial cell biology, specifically by modulating ACE2 expression. Given that ACE2 serves as a primary entry receptor for SAR…
This research highlights Thymosin α-1 as a potent immunomodulator with the capacity to reprogram tumor-associated macrophages, shifting them from a pro-tumorigenic M2 state to an anti-tumor M1 phenotype. This repolari…
This unique case highlights the critical need to understand atypical immune responses in immunocompromised individuals with SARS-CoV-2 and other viral infections. The absence of antibody production in this long-term a…
This study provides compelling evidence that Thymosin α1, an immunomodulatory peptide, can significantly improve survival and immune function in patients with HBV-related ACLF, a condition with historically poor progn…
This study provides compelling evidence that Thymosin alpha 1 can significantly improve outcomes for COVID-19 patients, particularly by reducing mortality and inflammation. The observed benefits suggest its potential …
This study provides compelling evidence that the synergistic combination of Xuebijing and thymosinα1 offers a potent therapeutic strategy for patients battling severe pneumonia complicated by sepsis. The significant i…
This study provides compelling evidence that Thymosin α1 can significantly reduce the incidence and severity of radiation pneumonitis, a major dose-limiting toxicity in lung cancer treatment. The ability to prevent su…
This study provides compelling evidence that combining Thymosin α1 with blood purification offers a promising new therapeutic strategy for managing severe shock, potentially leading to a significant reduction in patie…
This study provides compelling evidence that Thymosin alpha 1 acts as a potent immunomodulatory adjuvant, significantly enhancing the anti-tumor effects of HIPEC in an aggressive model of peritoneal metastases. The ob…
This pilot trial provides compelling evidence that Thymalfasin could be a valuable immunomodulatory therapy for hospitalized COVID-19 patients suffering from hypoxemia and lymphocytopenia. The observed improvements in…
This study provides a robust and highly sensitive analytical tool for the comprehensive quality control of thymalfasin, significantly enhancing the ability to detect and quantify potentially harmful impurities. The id…
This pilot study provides early evidence that immunomodulatory therapies like etanercept and alpha-1 antitrypsin could significantly enhance the success of autologous islet transplantation by reducing early inflammato…
This meta-analysis provides strong evidence that Thymosin alpha1, an immunomodulatory peptide, significantly improves critical clinical outcomes in adult COVID-19 patients, including reducing mortality and the need fo…
This research highlights a promising strategy to overcome immune suppression associated with HIPEC and significantly improve its therapeutic efficacy. By boosting the body's natural anti-cancer defenses, thymosin α1 c…
This review underscores the significant potential of Thymosin α-1 (Tα-1) to revolutionize cancer treatment strategies. By enhancing the body's natural anti-tumor immune response and potentially mitigating the side eff…